CN Patent

CN107405333A — 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物

Assigned to Verseon Corp · Expires 2017-11-28 · 8y expired

What this patent protects

尤其提供了可用于抑制凝血酶和/或激肽释放酶的多取代的芳族化合物，所述化合物包括被取代的吡唑基。此外提供了药物组合物。还提供了治疗和预防某些疾病或病症的方法，所述疾病或病症适合通过抑制凝血酶和/或激肽释放酶来治疗或预防。

USPTO Abstract

尤其提供了可用于抑制凝血酶和/或激肽释放酶的多取代的芳族化合物，所述化合物包括被取代的吡唑基。此外提供了药物组合物。还提供了治疗和预防某些疾病或病症的方法，所述疾病或病症适合通过抑制凝血酶和/或激肽释放酶来治疗或预防。

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN107405333A
Jurisdiction: CN
Classification: —
Expires: 2017-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Verseon Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.